As DARA is approaching uncharted waters w/ their application pending in terms of timeline, it is fair to suggest the FDA sees the merits but sent mgt back to the drawing board as they obviously incompently bungled the filing by failing to satisfactorily justify the request.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.